Clinical UpdatesGLP-1 therapyobesity treatment
Five Oral Obesity Drugs That Could Rival Eli Lilly’s Orforglipron in the Weight Loss Arena
By MedXY|Oct 3, 2025
Eli Lilly’s oral GLP-1 drug orforglipron marks a milestone in obesity treatment, yet competition from novel oral therapies by Novo Nordisk, Viking Therapeutics, Roche, Terns Pharmaceuticals, and Rhythm Pharmaceuticals is intensifying,